Brief: Ikena Oncology Outlines Key Priorities And Provides Corporate Updates

ImageneBio

18/01/2024 22:16

Jan 18 (Reuters) - Ikena Oncology Inc  IKNA.O :
    * IKENA ONCOLOGY OUTLINES KEY PRIORITIES AND PROVIDES
CORPORATE
UPDATES
    * IKENA ONCOLOGY INC: IK-930 OPTIMIZED FORMULATION NOW IN
CLINIC;
ON TRACK TO DELIVER ADDITIONAL MONOTHERAPY DATA IN 2H 2024
    * IKENA ONCOLOGY INC: ENDED 2023 IN STRONG FINANCIAL
POSITION WITH
APPROXIMATELY $175 MILLION IN CASH; RUNWAY EXTENDED INTO 2H 2026
    * IKENA ONCOLOGY INC: IK-595 FIRST COHORT TREATED AND
CLEARED
SAFETY EVALUATION WINDOW
    * IKENA ONCOLOGY INC: COMPANY HAS MADE STRATEGIC DECISION TO
REALLOCATE RESOURCES FROM DISCOVERY ORGANIZATION TO CLINICAL
PROGRAMS
    * IKENA ONCOLOGY INC: THIS INCLUDES A WORKFORCE REDUCTION OF
APPROXIMATELY 35%, TO BE IMPLEMENTED OVER COURSE OF Q1 OF 2024

Source text for Eikon:  ID:nGNX5RFrST 
Further company coverage:  IKNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))